Nuvectis Pharma (NVCT) Non-Current Deffered Revenue (2021)
Nuvectis Pharma's (NVCT) quarterly Non-Current Deffered Revenue came in at $824000.0 in Q4 2021.
Nuvectis Pharma (NVCT) Non-Current Deffered Revenue (2021) Analysis & Trends
Nuvectis Pharma has disclosed Non-Current Deffered Revenue across 1 years of filings, most recently posting $824000.0 for Q4 2021.
- Non-Current Deffered Revenue for Q4 2021 came in at $824000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $824000.0 (changed N/A YoY), and the FY2021 annual result was $824000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $824000.0 for Q4 2021 at Nuvectis Pharma.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $824000.0 in Q4 2021 to a low of $824000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nuvectis Pharma | 274.90 Mn | 274.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 824,000.00 |